المؤلفون: Chouik, Yasmina, Francoz, Claire, De Martin, Eleonora, Guillaud, Olivier, Abergel, Armand, Altieri, Mario, Barbier, Louise, Chazouillères, Olivier, Conti, Filomena, Corpechot, Christophe, Dharancy, Sebastien, Durand, François, Duvoux, Christophe, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Houssel-Debry, Pauline, Kamar, Nassim, Minello, Anne, Neau-Cransac, Martine, Pageaux, Georges-Philippe, Radenne, Sylvie, Roux, Olivier, Saliba, Faouzi, Samuel, Didier, Vanlemmens, Claire, Woehl-Jaegle, Marie-Lorraine, Leroy, Vincent, Duclos-Vallée, Jean-Charles, Dumortier, Jerôme

المساهمون: Université de Lille, Inserm, CHU Lille, Hospices Civils de Lyon HCL, Centre de recherche sur l'Inflammation CRI (UMR_S_1149 / ERL_8252 / U1149), Physiopathologie et traitement des maladies du foie, Université Claude Bernard Lyon 1 UCBL, Institut Pascal IP, Hôpital Côte de Nacre CHU Caen, Hôpital Trousseau, Centre de Recherche Saint-Antoine CRSA, CHU Pitié-Salpêtrière AP-HP, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Hôpital Henri Mondor, Centre Hospitalier Universitaire de Nice CHU Nice, Hôpital de la Timone CHU - APHM TIMONE, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) IAB, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, Epidémiologie et recherche clinique en oncologie digestive (CTM UMR 1231) EPICAD, Hôpital Haut-Lévêque CHU Bordeaux, CHU Montpellier, Hôpital de la Croix-Rousse CHU - HCL, Centre Hépato-Biliaire Hôpital Paul Brousse CHB, Physiopathogénèse et Traitement des Maladies du Foie, Hôpital JeanMinjoz, Hôpital de Hautepierre Strasbourg

مصطلحات موضوعية: early infection, fulminant hepatitis, immunosuppression, sepsis, survival

الوصف: Background and Aims Autoimmune hepatitis (AIH) is a rare indication (<5%) for liver transplantation (LT). The aim of this study was to describe the early outcome after LT for AIH. Methods A multicenter retrospective nationwide study including all patients aged ≥16 transplanted for AIH in France was conducted. Occurrences of biliary and vascular complications, rejection, sepsis, retransplantation and death were collected during the first year after LT. Results A total of 344 patients (78.8% of women, 17.0% of (sub)fulminant hepatitis and 19.2% of chronic liver diseases transplanted in the context of acute-on-chronic liver failure [ACLF]) were included, with a median age at LT of 43.6 years. Acute rejection, sepsis, biliary and vascular complications occurred in respectively 23.5%, 44.2%, 25.3% and 17.4% of patients during the first year after LT. One-year graft and patient survivals were 84.3% and 88.0% respectively. The main cause of early death was sepsis. Pre-LT immunosuppression was not associated with an increased risk for early infections or surgical complications. Significant risk factors for septic events were LT in the context of (sub)fulminant hepatitis or ACLF, acute kidney injury at the time of LT (AKI) and occurrence of biliary complications after LT. AKI was the only independent factor associated with graft (HR = 2.5; 95% CI: 1.1–5.4; p = .02) and patient survivals (HR = 2.6; 95% CI: 1.0–6.5; p = .04). Conclusion Early prognosis is good after LT for AIH and is not impacted by pre-LT immunosuppression but by the presence of AKI at the time of LT. ; 43

وصف الملف: application/rdf+xml; charset=utf-8; application/pdf

العلاقة: Liver International; Liver Int; http://hdl.handle.net/20.500.12210/100668Test

الإتاحة: https://doi.org/20.500.12210/100668Test
https://hdl.handle.net/20.500.12210/100668Test

المؤلفون: Chouik, Yasmina, Chazouillères, Olivier, Francoz, Claire, De Martin, Eleonora, Guillaud, Olivier, Abergel, Armand, Altieri, Mario, Barbier, Louise, Besch, Camille, Conti, Filomena, Corpechot, Christophe, Dharancy, Sebastien, Durand, François, Duvoux, Christophe, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Houssel-Debry, Pauline, Kamar, Nassim, Maucort-Boulch, Delphine, Minello, Anne, Neau-Cransac, Martine, Pageaux, Georges-Philippe, Radenne, Sylvie, Roux, Olivier, Saliba, Faouzi, Serée, Olivier, Samuel, Didier, Vanlemmens, Claire, Woehl-Jaegle, Marie-Lorraine, Leroy, Vincent, Duclos-Vallée, Jean-Charles, Dumortier, Jerôme

المساهمون: Université de Lille, Inserm, CHU Lille, Université Claude Bernard Lyon 1 UCBL, Centre de Recherche Saint-Antoine UMRS893, Centre de recherche sur l'Inflammation CRI (UMR_S_1149 / ERL_8252 / U1149), Physiopathologie et traitement des maladies du foie, Hôpital Edouard Herriot CHU - HCL, CHU Estaing Clermont-Ferrand, Centre Hospitalier Régional Universitaire de Tours CHRU Tours, Centre de Recherche Saint-Antoine CRSA, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) IAB, Lipides - Nutrition - Cancer Dijon - U1231 LNC, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers ANTICIPE

مصطلحات موضوعية: biliary complication, chronic rejection, recurrence, sepsis, survival

الوصف: Background & Aims Autoimmune hepatitis (AIH) is a rare indication for liver transplantation (LT). The aims of this study were to evaluate long-term survival after LT for AIH and prognostic factors, especially the impact of recurrent AIH (rAIH). Methods A multicentre retrospective nationwide study including all patients aged ≥16 transplanted for AIH in France was conducted. Early deaths and retransplantations (≤6 months) were excluded. Results The study population consisted of 301 patients transplanted from 1987 to 2018. Median age at LT was 43 years (IQR, 29.4–53.8). Median follow-up was 87.0 months (IQR, 43.5–168.0). Seventy-four patients (24.6%) developed rAIH. Graft survival was 91%, 79%, 65% at 1, 10 and 20 years respectively. Patient survival was 94%, 84% and 74% at 1, 10 and 20 years respectively. From multivariate Cox regression, factors significantly associated with poorer patient survival were patient age ≥58 years (HR = 2.9; 95% CI, 1.4–6.2; p = 0.005) and occurrence of an infectious episode within the first year after LT (HR = 2.5; 95% CI, 1.2–5.1; p = 0.018). Risk factors for impaired graft survival were: occurrence of rAIH (HR = 2.7; 95% CI, 1.5–5.0; p = 0.001), chronic rejection (HR = 2.9; 95% CI, 1.4–6.1; p = 0.005), biliary (HR = 2.0; 95% CI, 1.2–3.4; p = 0.009), vascular (HR = 1.8; 95% CI, 1.0–3.1; p = 0.044) and early septic (HR = 2.1; 95% CI, 1.2–3.5; p = 0.006) complications. Conclusion Our results confirm that survival after LT for AIH is excellent. Disease recurrence and chronic rejection reduce graft survival. The occurrence of an infectious complication during the first year post-LT identifies at-risk patients for graft loss and death. ; 43;5

وصف الملف: application/rdf+xml; charset=utf-8; application/pdf

العلاقة: Liver International; Liver Int; http://hdl.handle.net/20.500.12210/100628Test

الإتاحة: https://doi.org/20.500.12210/100628Test
https://hdl.handle.net/20.500.12210/100628Test

المؤلفون: Meunier, Lucy, De Martin, Eleonora, Delire, Bénédicte, Jacot, Wiliam, Guiu, Severine, Zahhaf, Amel, Larrey, Dominique, Horsmans, Yves

المساهمون: French Association of Liver Research

المصدر: JHEP Reports ; page 101098 ; ISSN 2589-5559

مصطلحات موضوعية: Gastroenterology, Hepatology, Immunology and Allergy, Internal Medicine

الإتاحة: https://doi.org/10.1016/j.jhepr.2024.101098Test
https://api.elsevier.com/content/article/PII:S2589555924001022?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2589555924001022?httpAccept=text/plainTest

المؤلفون: Sacleux, Sophie-Caroline-, Ichaï, Philippe, Coilly, Audrey, Boudon, Marc, Lemaitre, Elise, Sobesky, Rodolphe, De Martin, Eleonora, Cailliez, Valérie, Kounis, Ilias, Poli, Edoardo, Ordan, Marie-Amélie, Pascale, Alina, Duclos-Vallée, Jean-Charles, Feray, Cyrille, Azoulay, Daniel, Vibert, Eric, Cherqui, Daniel, Adam, René, Samuel, Didier, Saliba, Faouzi

المصدر: JHEP Reports ; volume 6, issue 1, page 100929 ; ISSN 2589-5559

مصطلحات موضوعية: Gastroenterology, Hepatology, Immunology and Allergy, Internal Medicine

الإتاحة: https://doi.org/10.1016/j.jhepr.2023.100929Test
https://api.elsevier.com/content/article/PII:S2589555923002604?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2589555923002604?httpAccept=text/plainTest

المؤلفون: Andrade, Raúl J, Aithal, Guruprasad P, de Boer, Ynto S, Liberal, Rodrigo, Gerbes, Alexander, Regev, Arie, Terziroli Beretta-Piccoli, Benedetta, Schramm, Christoph, Kleiner, David E, De Martin, Eleonora, Kullak-Ublick, Gerd A, Stirnimann, Guido, Devarbhavi, Harshad, Vierling, John M, Manns, Michael P, Sebode, Marcial, Londoño, Maria Carlota, Avigan, Mark, Robles-Diaz, Mercedes, García-Cortes, Miren, Atallah, Edmond, Heneghan, Michael, Chalasani, Naga, Trivedi, Palak J, Hayashi, Paul H, Taubert, Richard, Fontana, Robert J, Weber, Sabine, Oo, Ye Htun, Zen, Yoh, IAIHG Consortium, EASL DHILI Consortium

المصدر: Andrade, Raúl J; Aithal, Guruprasad P; de Boer, Ynto S; Liberal, Rodrigo; Gerbes, Alexander; Regev, Arie; Terziroli Beretta-Piccoli, Benedetta; Schramm, Christoph; Kleiner, David E; De Martin, Eleonora; Kullak-Ublick, Gerd A; Stirnimann, Guido; Devarbhavi, Harshad; Vierling, John M; Manns, Michael P; Sebode, Marcial; Londoño, Maria Carlota; Avigan, Mark; Robles-Diaz, Mercedes; García-Cortes, Miren; Atallah, Edmond; Heneghan, Michael; Chalasani, Naga; Trivedi, Palak J; Hayashi, Paul H; Taubert, Richard; Fontana, Robert J; Weber, Sabine; Oo, Ye Htun; Zen, Yoh; et al; IAIHG Consortium; EASL DHILI Consortium (2023). Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. Journal of ....

مصطلحات موضوعية: Clinic for Clinical Pharmacology and Toxicology, 610 Medicine & health, Hepatology

الوصف: Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition.

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/237582/1/1_s2.0_S0168827823003203_main.pdfTest; info:pmid/37164270; urn:issn:0168-8278

الإتاحة: https://doi.org/10.5167/uzh-237582Test
https://doi.org/10.1016/j.jhep.2023.04.033Test
https://www.zora.uzh.ch/id/eprint/237582Test/
https://www.zora.uzh.ch/id/eprint/237582/1/1_s2.0_S0168827823003203_main.pdfTest

المؤلفون: Kolla, Epiphane, Weill, Alain, Zaidan, Mohamad Waznul Adly Mohd, de Martin, Eléonora, Colin de Verdiere, Sylvie, Semenzato, Laura, Zureik, Mahmoud, Grimaldi, Lamiae

المساهمون: EPI-PHARE (EPI-PHARE), Caisse nationale d'assurance maladie des travailleurs salariés CNAMTS -Agence nationale de sécurité du médicament et des produits de santé Saint-Denis (ANSM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Néphrologie CHU Bicêtre, Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Foch Suresnes

المصدر: ISSN: 2574-3805 ; JAMA Network Open ; https://hal.science/hal-04294687Test ; JAMA Network Open, 2023, 6 (11), ⟨10.1001/jamanetworkopen.2023.42006⟩.

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الوصف: International audience ; Importance: Solid organ transplant recipients are at high risk of severe infection with SARS-CoV-2 compared with the general population. However, factors associated with COVID-19-related severity in this population are still insufficiently explored in the literature. Objective: To examine which health conditions and immunosuppressive drugs for preventing graft rejection are associated with the risk of COVID-19-related hospitalization in solid organ transplant recipients. Design, Setting, and Participants: Using the French National Health Data System, this cohort study assessed patients of any age who received transplants between their date of birth and entry into the cohort on February 15, 2020. The cohort was followed up between February 15, 2020, and July 31, 2022. Exposures: Immunosuppressive drugs, including steroids, and health conditions (age, sex, and comorbidities). Main Outcomes and Measures: The main outcome was hospitalization for COVID-19, defined by main diagnostic International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Factors associated with the outcome were identified with a nonconditional logistic regression. Confounding by indication was controlled using a multivariable model with adjustment for individual confounders. Each transplanted organ was examined separately. Results: Overall, 60 456 participants (median [IQR] age, 59 [47-67] years; 63.7% male) were included in the study, of whom 41 463 (68.6%) had kidney transplants, 14 464 (23.9%) had liver transplants, 5327 (8.8%) had heart transplants, and 2823 (4.6%) had lung transplants. Among them, 12.7% of kidney transplant recipients, 6.4% of liver transplant recipients, 12.9% of heart transplant recipients, and 18.0% of lung transplant recipients were hospitalized for COVID-19. In kidney transplant recipients, steroids (adjusted odds ratio [AOR], 1.60; 95% CI, 1.49-1.73) and mycophenolic acid (AOR, 1.37; 95% CI, 1.25-1.51) were associated with a high risk of ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37934496; hal-04294687; https://hal.science/hal-04294687Test; https://hal.science/hal-04294687/documentTest; https://hal.science/hal-04294687/file/kolla_2023_oi_231216_1698415363.40702.pdfTest; PUBMED: 37934496

الإتاحة: https://doi.org/10.1001/jamanetworkopen.2023.42006Test
https://hal.science/hal-04294687Test
https://hal.science/hal-04294687/documentTest
https://hal.science/hal-04294687/file/kolla_2023_oi_231216_1698415363.40702.pdfTest

المؤلفون: Chouik, Yasmina, Francoz, Claire, de Martin, Eleonora, Guillaud, Olivier, Abergel, Armand, Altieri, Mario, Barbier, Louise, Besch, Camille, Chazouillères, Olivier, Conti, Filomena, Corpechot, Christophe, Dharancy, Sébastien, Durand, François, Duvoux, Christophe, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Houssel-Debry, Pauline, Kamar, Nassim, Minello, Anne, Neau-Cransac, Martine, Pageaux, Georges-Philippe, Radenne, Sylvie, Roux, Olivier, Saliba, Faouzi, Samuel, Didier, Vanlemmens, Claire, Woehl-Jaegle, Marie-Lorraine, Leroy, Vincent, Duclos-Vallée, Jean-Charles, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Hôpital Beaujon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Edouard Herriot CHU - HCL, Clinique de la Sauvegarde Lyon, CHU Estaing Clermont-Ferrand, CHU Clermont-Ferrand, Hôpital Côte de Nacre CHU Caen, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Hôpital de Hautepierre Strasbourg, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Henri Mondor Créteil, Hôpital de la Conception CHU - APHM (LA CONCEPTION), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire Grenoble (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), CHU Pontchaillou Rennes, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Néphrologie et Transplantation d'organes CHU Toulouse, Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer Dijon - U1231 (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Fondation Léon Bouchut

المصدر: ISSN: 1478-3223.

مصطلحات موضوعية: early infection, fulminant hepatitis, immunosuppression, sepsis, survival, MESH: Humans, MESH: Female, MESH: Adult, MESH: Liver Transplantation, MESH: Hepatitis, Autoimmune, MESH: Massive Hepatic Necrosis, MESH: Retrospective Studies, MESH: Sepsis, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: Background and aims: Autoimmune hepatitis (AIH) is a rare indication (<5%) for liver transplantation (LT). The aim of this study was to describe the early outcome after LT for AIH.Methods: A multicenter retrospective nationwide study including all patients aged ≥16 transplanted for AIH in France was conducted. Occurrences of biliary and vascular complications, rejection, sepsis, retransplantation and death were collected during the first year after LT.Results: A total of 344 patients (78.8% of women, 17.0% of (sub)fulminant hepatitis and 19.2% of chronic liver diseases transplanted in the context of acute-on-chronic liver failure [ACLF]) were included, with a median age at LT of 43.6 years. Acute rejection, sepsis, biliary and vascular complications occurred in respectively 23.5%, 44.2%, 25.3% and 17.4% of patients during the first year after LT. One-year graft and patient survivals were 84.3% and 88.0% respectively. The main cause of early death was sepsis. Pre-LT immunosuppression was not associated with an increased risk for early infections or surgical complications. Significant risk factors for septic events were LT in the context of (sub)fulminant hepatitis or ACLF, acute kidney injury at the time of LT (AKI) and occurrence of biliary complications after LT. AKI was the only independent factor associated with graft (HR = 2.5; 95% CI: 1.1-5.4; p = .02) and patient survivals (HR = 2.6; 95% CI: 1.0-6.5; p = .04).Conclusion: Early prognosis is good after LT for AIH and is not impacted by pre-LT immunosuppression but by the presence of AKI at the time of LT.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36577700; hal-04166795; https://hal.science/hal-04166795Test; PUBMED: 36577700

الإتاحة: https://doi.org/10.1111/liv.15500Test
https://hal.science/hal-04166795Test

المؤلفون: Chouik, Yasmina, Chazouillères, Olivier, Francoz, Claire, de Martin, Eleonora, Guillaud, Olivier, Abergel, Armand, Altieri, Mario, Barbier, Louise, Besch, Camille, Conti, Filomena, Corpechot, Christophe, Dharancy, Sébastien, Durand, François, Duvoux, Christophe, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie‐noëlle, Houssel-Debry, Pauline, Kamar, Nassim, Maucort-Boulch, Delphine, Minello, Anne, Neau-Cransac, Martine, Pageaux, Georges‐philippe, Radenne, Sylvie, Roux, Olivier, Saliba, Faouzi, Serée, Olivier, Samuel, Didier, Vanlemmens, Claire, Woehl-Jaegle, Marie‐lorraine, Leroy, Vincent, Duclos-Vallée, Jean‐charles, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire CHU Grenoble (CHUGA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Biostatistiques Lyon, Lipides - Nutrition - Cancer Dijon - U1231 (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation Léon Bouchut

المصدر: ISSN: 1478-3223.

مصطلحات موضوعية: biliary complication, chronic rejection, recurrence, sepsis, survival, [SDV]Life Sciences [q-bio]

الوصف: International audience ; Background & aims: Autoimmune hepatitis (AIH) is a rare indication for liver transplantation (LT). The aims of this study were to evaluate long-term survival after LT for AIH and prognostic factors, especially the impact of recurrent AIH (rAIH).Methods: A multicentre retrospective nationwide study including all patients aged ≥16 transplanted for AIH in France was conducted. Early deaths and retransplantations (≤6 months) were excluded.Results: The study population consisted of 301 patients transplanted from 1987 to 2018. Median age at LT was 43 years (IQR, 29.4-53.8). Median follow-up was 87.0 months (IQR, 43.5-168.0). Seventy-four patients (24.6%) developed rAIH. Graft survival was 91%, 79%, 65% at 1, 10 and 20 years respectively. Patient survival was 94%, 84% and 74% at 1, 10 and 20 years respectively. From multivariate Cox regression, factors significantly associated with poorer patient survival were patient age ≥58 years (HR = 2.9; 95% CI, 1.4-6.2; p = 0.005) and occurrence of an infectious episode within the first year after LT (HR = 2.5; 95% CI, 1.2-5.1; p = 0.018). Risk factors for impaired graft survival were: occurrence of rAIH (HR = 2.7; 95% CI, 1.5-5.0; p = 0.001), chronic rejection (HR = 2.9; 95% CI, 1.4-6.1; p = 0.005), biliary (HR = 2.0; 95% CI, 1.2-3.4; p = 0.009), vascular (HR = 1.8; 95% CI, 1.0-3.1; p = 0.044) and early septic (HR = 2.1; 95% CI, 1.2-3.5; p = 0.006) complications.Conclusion: Our results confirm that survival after LT for AIH is excellent. Disease recurrence and chronic rejection reduce graft survival. The occurrence of an infectious complication during the first year post-LT identifies at-risk patients for graft loss and death.

العلاقة: hal-04150813; https://hal.science/hal-04150813Test

الإتاحة: https://doi.org/10.1111/liv.15552Test
https://hal.science/hal-04150813Test

المؤلفون: Andrade-Bellido, Raúl Jesús, Aithal, Guruprasad P., De Boer, Ynto S., Liberal, Rodrigo, Gerbes, Alexander L, Regev, Arie, Terziroli Beretta-Piccoli, Benedetta, Schramm, Christoph, Kleiner, David E., De Martin, Eleonora, Kullak-Ublick, Gerd A, Stirnimann, Guido, Devarbhavi, Harshad, Vierling, John M., Manns, Michael P., Sebode, Marcial, Londoño, María Carlota, Avigan, Mark, Robles-Díaz, María Mercedes, García-Cortés, Miren, Atallah, Edmond, Heneghan, Michael, Chalasani, Naga, Trivedi, Palak J., Hayashi, Paul H., Taubert, Richard, Fontana, Robert J., Weber, Sabine, Oo, Ye Htun, Zen, Yoh, Licata, Anna, Lucena-González, María Isabel, Mieli-Vergani, Giorgina, Vergani, Diego, Bjornsson, Einar S.

مصطلحات موضوعية: Hígado - Enfermedades, Hígado - Efectos de los medicamentos, Liver injury, Hepatotoxicity, Drug-induced liver injury, DILI, Autoimmune hepatitis, AIH, DI-ALH, Drug-induced autoimmune-like hepatitis, Epidemiology, Diagnosis, Management, Outcome

الوصف: Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition. ; Funding for open access charge: Universidad de Málaga/CBUA

العلاقة: Raúl J. Andrade, Guruprasad P. Aithal, Ynto S. de Boer, Rodrigo Liberal, Alexander Gerbes, Arie Regev, Benedetta Terziroli Beretta-Piccoli, Christoph Schramm, David E. Kleiner, Eleonora De Martin, Gerd A. Kullak-Ublick, Guido Stirnimann, Harshad Devarbhavi, John M. Vierling, Michael P. Manns, Marcial Sebode, Maria Carlota Londoño, Mark Avigan, Mercedes Robles-Diaz, Miren García-Cortes, Edmond Atallah, Michael Heneghan, Naga Chalasani, Palak J. Trivedi, Paul H. Hayashi, Richard Taubert, Robert J. Fontana, Sabine Weber, Ye Htun Oo, Yoh Zen, Anna Licata, M Isabel Lucena, Giorgina Mieli-Vergani, Diego Vergani, Einar S. Björnsson, Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report, Journal of Hepatology, 2023, 1-14; https://hdl.handle.net/10630/27267Test

الإتاحة: https://doi.org/10.1016/j.jhep.2023.04.033Test
https://hdl.handle.net/10630/27267Test

المؤلفون: Codoni, Greta, Kirchner, Theresa, Engel, Bastian, Villamil, Alejandra Maria, Efe, Cumali, Stättermayer, Albert Friedrich, Weltzsch, Jan Philipp, Sebode, Marcial, Bernsmeier, Christine, Lleo, Ana, Gevers, Tom Jg, Kupčinskas, Limas, Castiella, Agustin, Pinazo, Jose, De Martin, Eleonora, Bobis, Ingrid, Sandahl, Thomas Damgaard, Pedica, Federica, Invernizzi, Federica, Del Poggio, Paolo, Bruns, Tony, Kolev, Mirjam, Semmo, Nasser, Bessone, Fernando, Giguet, Baptiste, Poggi, Guido, Ueno, Masayuki, Jang, Helena, Elpek, Gülsüm Özlem, Soylu, Neşe Karadağ, Cerny, Andreas, Wedemeyer, Heiner, Vergani, Diego, Mieli-Vergani, Giorgina, Lucena, M Isabel, Andrade, Raul J, Zen, Yoh, Taubert, Richard, Terziroli Beretta-Piccoli, Benedetta

المصدر: Codoni , G , Kirchner , T , Engel , B , Villamil , A M , Efe , C , Stättermayer , A F , Weltzsch , J P , Sebode , M , Bernsmeier , C , Lleo , A , Gevers , T J , Kupčinskas , L , Castiella , A , Pinazo , J , De Martin , E , Bobis , I , Sandahl , T D , Pedica , F , Invernizzi , F , Del Poggio , P , Bruns , T , Kolev , M , Semmo , N , ....

الوصف: BACKGROUND & AIMS: Liver injury with autoimmune features after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is increasingly reported. We investigated a large international cohort of individuals with acute hepatitis arising after SARS-CoV-2 vaccination, focusing on histological and serological features. METHODS: Individuals without known pre-existing liver diseases and transaminase levels ≥5x the upper limit of normal within 3 months after any anti-SARS-CoV-2 vaccine, and available liver biopsy were included. Fifty-nine patients were recruited; 35 females; median age 54 years. They were exposed to various combinations of mRNA, vectorial, inactivated and protein-based vaccines. RESULTS: Liver histology showed predominantly lobular hepatitis in 45 (76%), predominantly portal hepatitis in 10 (17%), and other patterns in four (7%) cases; seven had fibrosis Ishak stage ≥3, associated with more severe interface hepatitis. Autoimmune serology, centrally tested in 31 cases, showed anti-antinuclear antibody in 23 (74%), anti-smooth muscle antibody in 19 (61%), anti-gastric parietal cells in eight (26%), anti-liver kidney microsomal antibody in four (13%), and anti-mitochondrial antibody in four (13%) cases. Ninety-one percent were treated with steroids ± azathioprine. Serum transaminase levels improved in all cases and were normal in 24/58 (41%) after 3 months, and in 30/46 (65%) after 6 months. One patient required liver transplantation. Of 15 patients re-exposed to SARS-CoV-2 vaccines, three relapsed. CONCLUSION: Acute liver injury arising after SARS-CoV-2 vaccination is frequently associated with lobular hepatitis and positive autoantibodies. Whether there is a causal relationship between liver damage and SARS-CoV-2 vaccines remains to be established. A close follow-up is warranted to assess the long-term outcomes of this condition. IMPACT AND IMPLICATIONS: Cases of liver injury after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) have ...

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/d3d1e63c-1d18-4b3d-a20f-261afed01757Test

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100605Test
https://cris.maastrichtuniversity.nl/en/publications/d3d1e63c-1d18-4b3d-a20f-261afed01757Test